• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    eBook
    Top Features
    Additive Manufacturing at the Point of Care

    Six Orthopedic Firms En Route to Significant Market Disruption

    The Next Steps for Recovery and Rehab

    Scratching the Surface: A Roundtable on Coatings and Treatments

    Influencers on the Orthopedic Implant Manufacturing Market
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Integra LifeSciences Founder Dr. Richard Caruso Passes Away

    FDA Clears CTL Amedica's Navigation Instrument System

    FundamentalVR Raises $20 Million in Series B Funding

    Bioventus Achieves Strong Growth in Q2 2022

    Bone Void Fillers Market Growing at 6%
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    The ODT 2022 Top 10 Orthopedic Device Companies

    Additive Manufacturing at the Point of Care

    Six Orthopedic Firms En Route to Significant Market Disruption

    The Genetic Risk for Joint Replacement Failure

    The Case for Using Historical Control in Clinical Trial Design
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Orthopedic Device Evolution is Driven by Precision Technology

    mdHACM Allografts Demonstrate Potential in Treating Knee Osteoarthritis

    Radically Improving Medicine & Surgery with Light Field Technology

    A Call to Action in Orthopedics: We Need to Personalize Every Single Hip and Knee Surgery

    Giving Knee Replacement Surgery a Much-Needed Update
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Braxton Manufacturing

    Life Science Outsourcing Inc.

    Modern Plastics

    Tiodize

    AV&R
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • eBook
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    Medical Device IP Strategy, Part II: Creating a Patent Strategy to Mitigate Risk

    U.S. patent law establishes the right of a patent owner to prevent others from making, using, selling, offering for sale a product claimed in a valid patent.

    Medical Device IP Strategy, Part II: Creating a Patent Strategy to Mitigate Risk
    Figure 1
    Gregory Grissett, Principal and Chair, Intellectual Property Group, Offit Kurman P.A.09.14.21
    The Monadnock region in southern New Hampshire (where I have the pleasure of living) is dominated by Mount Monadnock and tradition holds that “Monadnock” means “stands above the rest.” What does a mountainous region in New Hampshire have to do with IP strategy? Medical device companies with a thoughtful IP strategy typically have higher valuations, higher revenue, and more robust product offerings, compared to those without a thoughtful IP strategy. What does it take to develop and execute an effective patent strategy that stands above the rest? Part I described components of a robust patent strategy in the medical device sector. This part explains how to mitigate risk related to third-party patent rights.

    Foundational Laws Related to Patent Risk Mitigation and Freedom-to-Operate
    U.S. patent law establishes the broad right of a patent owner to prevent others from making, using, selling, offering for sale, or importing into the United States, a product or service that is claimed in a valid patent.1 When another company performs any of these infringing acts without permission from the patent owner, the patent owner is entitled to money damages and injunctive relief (i.e., the ability to bar a third party from selling a product in the U.S. covered by a patent).2

    Liability for direct patent infringement attaches to a company when 1) the patent owner proves a company’s product infringes a patent, and 2) the defendant-company fails to establish3 the patent claim is invalid or unenforceable. In addition, patent infringement liability can also attach to a company that induces a third party to infringe a patent claim. Inducement liability is established when the alleged infringer A) engages in conduct that induces or encourages a third party to infringe the patent, and B) had knowledge that the induced acts comprise patent infringement.4 For example, a medical device company can induce a doctor to infringe a method claim of a patent and be liable for patent infringement even though that company did not perform the infringing acts itself.

    Willful infringement is another risk. When willful infringement is established, a court may triple the damage award and/or add attorney’s fees.

    Finally, patent liability attaches only to companies found to infringe valid patent claims. Failure of a patent claim to comply with patentability principles renders that claim invalid and ineffective to prohibit infringers from selling a competing product.5

    U.S. patent litigation is complex and costly. The threat of money damages, injunctions, and defense costs are considerable incentives to design products that are unique and do not infringe the other’s patent rights.

    Why Should You Implement a Freedom-to-Operate Strategy?
    A freedom-to-operate (FTO) study can help a medical device company mitigate patent infringement risk by identifying and evaluating the extent and nature of patent risks associated with selling your product. FTO studies also guide the design and development of your product by directing a development toward solutions with lower risk. In addition, FTO studies give confidence to investors that their investment is not an investment in a lawsuit. Furthermore, formal patent opinions of counsel, which are often prepared during an FTO study, may be used as evidence to disprove both willful infringement and inducement infringement allegations.

    How Do You Conduct an FTO Analysis?
    FTO studies have four phases: 1) patent search or notification of patent rights, 2) infringement analysis, 3) design around activities, and 4) validity analysis (Figure 1).

    Identifying patents that are relevant to your company’s products is the first phase in an FTO study. This can include engaging a patent search firm to locate patents and published applications relevant to the product. Your company may receive a cease and desist letter asserting your company’s product infringes a patent. In any event, once potentially relevant patents are identified, preliminary analysis of the results can filter out irrelevant and expired patents.

    In phase 2, patent counsel analyzes all the patents found in phase 1. In phase 2, the claims, the specification, the patent file history, and relevant claim terms are construed.6 Then, the construed claims are compared to the product. If all the claim elements are found in the product, then the product infringes the claim. If any part of the claim is not present in the product, there is no infringement.

    For example, as shown in Figure 2, product A includes all the elements required in claim 1. Product B, however, does not have all required in claim 1—no grey gizmo—and therefore, does not literally infringe the claim. While this small difference may avoid literal infringement, a risk may still present because it is conceivable a court may find product B infringes the claim under Doctrine of Equivalents. Subtle details in this case can make all the difference. Phase 2 is where engaged patent counsel can help identify the contours of the patent rights so the product development team can understand how to proceed in development.


    Figure 2

    If the product does not literally or equivalently infringe the claim, there is low patent risk (green box in Figure 1) and the product has freedom-to-operate. If, however, the product at issue infringes the patent claim, design changes are considered in phase 3.

    Phase 3 is classic design around analysis. If the product can be modified to avoid the claim, infringement risk is minimized and freedom-to-operate is reasonably attained. Timing is important. If a PMA or 510(k) application has been filed, it may be very costly and time consuming to change the product. In those circumstances, business needs may require progression to phase 4: validity analysis.

    In phase 4, patent validity is analyzed. This may involve conducting a validity patent search to locate invalidating prior art. The results of the search can be used to prepare an opinion of counsel or be used as basis to invalidate the claims in an inter partes review or ex parte reexamination at the U.S. Patent & Trademark Office. Other grounds for invalidity, such as violation of the written description requirement or the claims are not properly enabled, can be considered. If there is a high probability the patent claim is invalid, there is low patent risk and the product has freedom-to-operate. Sometimes, the patent claim is not as susceptible to an invalidity attack. In that case, one can secure a license, purchase the patent, or proceed in the face of the risk.

    FTO studies result in practical business tools. First, the materials prepared during an FTO study can be used as a basis to address concerns an investor or strategic partner may have in view of the patent risks identified in phases 1-3. Second, companies that proactively conduct an FTO study are better positioned to address and manage due diligence. Third, FTO results may inform how important contracts are drafted as they relate to IP risk. Fourth, written patent opinions may be used as evidence to disprove a finding of willful infringement or inducement infringement of a patent claim. Finally, FTO studies can guide development toward wholly unique products and services that can result in independent patent rights.

    When Should You Conduct Patent Risk Mitigation Analysis?
    An FTO study should be conducted when driven by key commercial milestones or external events. For commercial milestones, timing is (almost) everything. In general, the earlier in the product development phase you can conduct an FTO study, the better. Early in the design and development phase, before design freeze occurs, you have the flexibility to make changes to the product in the face of patent risks uncovered by the FTO study. This allows you to make changes that are not (as) costly. In the medical device context, FTO studies should ideally occur before 1) significant capital outlay, 2) filing a 510(k) or PMA, and 3) commercial sales occur. The more finalized the product design, the more robust the FTO results will be.

    External events that require FTO studies may be investor due diligence or receipt of notice/cease & desist letter. Potential investors and strategic partners may require it prior to making their financial placements. In the case of notice/C&D letter, timely investigation and assessment of the claims in view of the product are critical. The key issue is to address this risk proactively and ahead of instances that are critical for business or capital development.

    Conclusion
    Patent infringement risk is significant in the medical device sector. Infringing a valid patent can result in significant damage awards and an injunction. The threat of money damages, injunctions, and defense costs are considerable incentives to design wholly unique products that do not infringe the rights of others. A proactive FTO study can help assess and manage this risk. Timing is important and earlier assessments allow your business to pivot to avoid and manage known risks. 

    References
    1. 35 U.S.C. §271
    2. 35 U.S.C. §284
    3. 35 U.S.C. §302-329
    4. 35 U.S.C. §271(b), Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (2011)
    5. 35 U.S.C. §101, §102 and § 103
    6. Claim construction is a fundamental and required step in evaluating any patent risk.
    Loading, Please Wait..

    Trending
    • MdHACM Allografts Demonstrate Potential In Treating Knee Osteoarthritis
    • Additive Manufacturing At The Point Of Care
    • Bioventus Launches DUROLANE In The U.S.
    • FundamentalVR Raises $20 Million In Series B Funding
    • Future Stars Of The Spine Industry: The Companies To Watch, 2021
    Breaking News
    • Integra LifeSciences Founder Dr. Richard Caruso Passes Away
    • FDA Clears CTL Amedica's Navigation Instrument System
    • FundamentalVR Raises $20 Million in Series B Funding
    • Bioventus Achieves Strong Growth in Q2 2022
    • Bone Void Fillers Market Growing at 6%
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Additive Manufacturing at the Point of Care
    • Six Orthopedic Firms En Route to Significant Market Disruption
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise
    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression
    Coatings World

    Latest Breaking News From Coatings World

    The BEHR & KILZ Brands Partner with Leanne Ford to Revitalize Her Historic American Home
    IGM Resins Acquires Litian
    Ingevity to Acquire Pavement Marking Materials Business, Ozark Materials
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TransMed7 Achieves First-in-Human for Heron Soft Tissue Biopsy Devices
    West Pharmaceutical Services Invests in Latch Medical
    Integra LifeSciences Founder Dr. Richard Caruso Passes Away
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Societal CDMO Inks Land Sell Deal
    RoosterBio and AGC Biologics to Accelerate Manufacturing of Cell and Exosome Therapies
    WuXi Advanced Therapies Enters Licensing Agreement with Janssen
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Johnson & Johnson to Discontinue Global Sales of Talc-Based Baby Powder
    Dr. Squatch To Launch a 2nd Star Wars Soap Collection
    Neopac Wins 2 European Tube Manufacturers Association Awards
    Happi

    Latest Breaking News From Happi

    Climate Change Drives Sustainability in Household & Personal Care
    Japonesque Acquires Foot Care Brand Barefoot Scientist
    Inolex Launches New Cannabis-Derived Ingredient for Sustainable Conditioning and Emulsification
    Ink World

    Latest Breaking News From Ink World

    BASF Breaks Ground on Riverfront Park in East Newark
    Roland DG Corporation to Relocate HQ to Miyakoda, Japan
    Gallus Launches Gallus One, Its First Fully Digital Inkjet Label Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FINAT reports decrease in labelstock consumption during first half of 2022
    Color-Logic partners to feature metallics at autumn events
    New Era Converting Machinery heads to The Battery Show
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Tranzonic Acquired by Private Investment Firm
    Monadnock Earns EcoVadis Gold Rating
    Suominen Announces Price Surcharges
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Integra LifeSciences Founder Dr. Richard Caruso Passes Away
    FDA Clears CTL Amedica's Navigation Instrument System
    FundamentalVR Raises $20 Million in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Celebrates Expansion of Silicon Carbide Production Facility in New Hampshire
    Applied Materials CTO Dr. Om Nalamasu Receives IEEE Frederik Philips Award
    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login